GD2 CAR T treatment induces durable remissions in high-risk neuroblastoma
From Bambino Gesù Children's Hospital in Rome comes a report that a third-generation CAR T cell therapy targeting GD2, designated GD2–CART01, induced durable remissions and long-term survival in children with high-risk ...